Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 0.44 |
| ▸ | GSK3B | P49841 | 5/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263673 | 0.91 | SCN9A (0.38) | GSK3AGSK3BCDK5CDK5R1PRKCA | |
| SCHEMBL4831754 | 0.90 | CREBBP (0.39) | GSK3AGSK3BCDK5CDK5R1SCN9A | |
| SCHEMBL874916 | 0.86 | PRKCA (0.50) | GSK3BPRKCAMMP12SCN9A | |
| SCHEMBL5422890 | 0.85 | PRKCA (0.41) | PRKCAMMP12SCN9A | |
| SCHEMBL14253244 | 0.78 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL14253260 | 0.78 | PRKCA (0.42) | PRKCAMMP12SCN9AKDM4AKDM5A | |
| SCHEMBL4829840 | 0.77 | PRKCA (0.49) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL14435330 | 0.77 | PRKCA (0.43) | GSK3BCDK5CDK5R1PRKCAMMP12 | |
| SCHEMBL14253180 | 0.76 | SCN9A (0.39) | PRKCAMMP12SCN9A | |
| SCHEMBL14253281 | 0.76 | SCN9A (0.48) | PRKCAMMP12SCN9ACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | GSK3A 906/4885GSK3B 751/4885CDK5 417/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | GSK3A 906/4885GSK3B 751/4885CDK5 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.